This copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact The Epoch Times Reprints.
The therapy was granted accelerated approval for its use in treating patients with metastatic and unremovable melanoma.
The new frontline therapy is the first in a decade intended to treat aggressive pancreatic adenocarcinoma.
The medication dilates blood vessels to prevent blood from clotting, lowering the risk of finger or toe amputation.
Over half of American doctors are under the impression the FDA approval process for new drugs and medical devices is more rigorous than it actually is.
The first drug to treat desmoid tumors shrank tumors in 41 percent of participants and improved quality of life with few side effects.
